Calcitriol administration in end-stage renal disease: Intravenous or oral?

Pediatric Nephrology

Volumn 10, Issue 3, 1996, Pages 331-336

  Quarles, L Darryl ^a   Indridason, Olafur Skuli ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Calcitriol; End stage renal disease; Secondary hyperparathyroidism

Indexed keywords

CALCITRIOL;

CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; DIALYSIS; HOMEOSTASIS; HUMAN; HYPERPHOSPHATEMIA; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PARATHYROID FUNCTION; PRIORITY JOURNAL; SECONDARY HYPERPARATHYROIDISM;

EID: 0029927314     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00866773     Document Type: Conference Paper

References (42)

1. Silver J (1992) Regulation of parathyroid hormone synthesis and secretion. In: Coe FL, Favus MJ (eds) Disorders of bone and mineral metabolism, Raven, New York, p 83
2. Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, Puschett JB (1988) Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab 67: 876-881
3. Portale AA, Holloran BP, Murphy MM, Morris RC Jr (1986) Oral intake of phosphorus can determine the serum concentration of 1,25-dihydroxyvitamin D by determining its production rate in humans. J Clin Invest 77: 7-12
4. Lopez-Hilker S, Galceran T, Chan Y-L, Rapp N, Martin KJ, Slatopolsky E (1986) Hypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure. J Clin Invest 78: 1097
5. Reichel H, Szabo A, Uhl J, Pesian S, Schmutz A, Schmidt-Gayk H, Ritz E (1993) Intermittent versus continuous administration of 1,25-dihydroxyvitamin D3 in experimental hyperparathyroidism. Kidney Int 44: 1259-1265
6. Patel SR, Ke HQ, Vanholder R, Hsu CH (1994) Inhibition of nuclear uptake of calcitriol receptor by uremic ultrafiltrate. Kidney Int 46: 129-133
7. Patel SR, Ke HQ, Hsu CH (1994) Regulation of calcitriol receptor and its mRNA in normal and renal failure rats. Kidney Int 45: 1020-1027
8. Koyama H, Nishizawa Y, Inaba M, Hino M, Drahl JM, Deluca HF, Morii H (1994) Impaired homologous upregulation of vitamin D receptor in rats with chronic renai failure. Am J Physiol 266: F706-F712
9. Fukuda N, Tanaka H, Tominaga Y, Fukagawa M, Kurokawa K, Seino Y (1993) Decreased 1,25-dihydroxyvitamin D3 receptor density is associated with a more severe form of parathyroid hyperplasia in chronic uremic patients. J Clin Invest 92: 1436-1443
10. Brown A, Dusso A, Slatopolsky E (1992) Vitamin D. In: Seldin DW, Giebisch G (eds) The kidney: physiology and pathophysiology, 2nd edn. Raven, New York, pp 1505-1552
11. Salusky IB, Goodman WG, Horst R, Segre GV, Kim L, Norris KC, Adams JS, Holloway M, Fine RN, Coburn JW (1990) Pharmacokinetics of calcitriol in continuous ambulatory and cycling peritoneal dialysis patients. Am J Kidney Dis 16: 126-132
12. Quartes LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA (1994) Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45: 1710-1721
13. Joffe P, Cintin C, Ladefoged SD, Rasmussen SN (1994) Pharmacokinetics of 1α-hydroxycholecalciferol after intraperitoneal, intravenous and oral administration in patients undergoing peritoneal dialysis. Clin Nephrol 41: 364-369
14. Nagant de Deuxchaisnes C, Devogelaer JP, De Nayer P (1990) Comparison of 1,25-(OHhDs levels after the administration of calcitriol and alfacalcidol. In: Vitamin D gene regulation structure - function analysis and clinical application. Proceedings of the Eighth Workshop on Vitamin D, Paris, France. DeGruyter, Berlin, New York, pp 314-315
15. Galbraith SC, Quarles LD (1993) Tertiary/refractory secondary hyperparathyroidism. In: Favus MJ (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 2nd edn. Raven, New York, pp 159-163
16. Krause MW, Hedinger CE (1985) Pathologic study of parathyroid glands in tertiary hyperparathyroidism. Hum Pathol 16: 772-784
17. Arnold A, Brown MF, Urena P, Gas RD, Sarfati E, Drueke TB (1995) Monoclonality of parathyroid tumors in chronic renal failure and primary parathyroid hyperplasia. J Clin Invest 95: 2047
18. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC (1993) Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 366: 575-580
19. Gogusev J, Duchambon P, Giovannini M, Sarfati E, Drueke TB (1996) Expression in pathologic parathyroid gland tissue of calcium receptor (CaR) and vitamin D receptor (VDR) gene message (mRNA). J Am Soc Nephrol 6: 961
20. Garrett JE, Capuano IV, Hammerland LG, Hung BCP, Brown EM, Hebert SC, Nemeth EF, Fuller F (1995) Molecular cloning and functional expression of human parathyroid calcium receptor cDNAs. J Biol Chem 270: 12919-12925
21. Hernandez AY, Torregrosa A, Campistol TV, Rodriguez TA, Nefrologia MS (1995) High phosphorus directly stimulates PTH secretion by human parathyroid tissue (abstract). J Am Soc Nephrol 6: 957
22. Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74: 2136-2143
23. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ (1989) Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 321: 274-279
24. Quarles LD, Davidai GA, Schwab SJ, Bartholomay DW, Lobaugh B (1988) Oral calcitriol and calcium: efficient therapy for uremic hyperparathyroidism. Kidney Int 34: 840-844
25. Oettinger CW, Oliver JC, Macon EJ (1992) The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients. J Am Soc Nephrol 3: 995-1001
26. Mazzaferro S, Pasquali M, Ballanti P, Bonucci E, SiDanza P, Sardella D, Taggi F, Coen G (1994) Intravenous versus oral calcitriol therapy in renal osteodystrophy: results of a prospective, pulsed and dise-comparable study. Miner Electrolyte Metab 20: 122-129
27. Coburn JW, Salusky IB, Norris KC, Goodman WG (1991) Oral and parenteral calcitriol for the management of end-stage renal disease. Contrib Nephrol 90: 166-182
28. Kiss D, Kraenzlin M (1994) Comparison of pulse intravenous (IV) versus oral (PO) calcitriol treatment of secondary hyperparathyroidism (HPT) in chronic hemodialysis patients (HD PTS) (abstract). J Am Soc Nephrol 5: 883
29. Rosenkranz AR, Thalhammer F, Holub, Novacek G, Traindl O (1994) Calcitriol - daily oral or intravenous putse therapy (abstract). J Am Soc Nephrol 5: 887
30. Goggins MO, Rao DS, Bhat S, Zasuwa G, Narins RG (1994) Hyperphosphatemia predicts a poor response to I.V. calcitriol (IVC) in hemodialysis (HD) patients (abstract). J Am Soc Nephrol 5: 879
31. Faugere M-C. Friedler RM, Malluche HH (1993) Efficacy and limitations of pulse I.V. and pulse oral 1,25 vit D therapy on bone disease in patients on chronic dialysis (abstract). J Am Soc Nephrol 4: 695
32. Song MM, Levine BS (1994) Oral pulse calcitriol versus intravenous calcitriol therapy in treatment of hyperparathyroidism in hemodialysis patients (abstract). J Am Soc Nephrol 5: 889
33. Fischer ER, Harris DC (1993) Comparison of intermittent oral and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism. Clin Nephrol 40: 216-220
34. Lee WT, Padayachi K, Collins JF, Cundy T (1994) A comparison of orai and intravenous alfacalcidol in the treatment of uremic hyperparathyroidism J Am Soc Nephrol 5: 1344-1348
35. Hamdy NAT, Kanis JA, Benton MNC, Brown CB, Juttman JR, Jordans JGM, Josse S, Meyrier A, Lins RL, Fairey IT (1995) Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 310: 358-363
36. Herrman P, Ritz E, Schmidt-Gayk H, Schafer I, Geyer J, Nonnast-Damel B, Koch KM, Weber U, Horl W, Haas-Worle A (1994) Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 67: 48-53
37. Moe S, Kraus M, Gassensmith C, Gannon F, North J, Peacock M (1994) A randomized trial of pulse versus daily oral calcitriol in CAPD patients (abstract). J Am Soc Nephrol 5: 854
38. Liou H-H, Chiang S-S, Huang TP, Shieh SD, Akmal M (1994) Comparative effect of oral or intravenous calcitriol on secondary hyperparathyroidism in chronic hemodialysis patients. Miner Electrolyte Metab 20: 97-102
39. Cannella G, Bonucci E, Rolla D, Ballanti P, Moriero E, Grandi RD, Augeri C, Claudiani F, Maio GD (1994) Evidence of healing of secondary hyperparathyroidism in chronically hemodialyzed uremic patients treated with long-term intravenous calcitriol. Kidney Int 46: 1124
40. Fukagawa M, Okazaki R, Takano K, Kaname S-Y, Ogata E, Kitaoka M, Harada S-I, Sekine N, Matsumoto T, Kurokawa K (1990) Regression of parathyroid hyperplasia by calcitriol-pulse therapy in patients on long-term dialysis. N Engl J Med 323: 421
41. Szabo A, Merke J, Beier E, Mall G, Ritz E (1989) 1,25(OH)2 Vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney Int 35: 1049-1056
42. Goodman WB, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46: 1160